Stockscreener 앱 받기
16.79
2.47%
-0.425
시간 외 거래:
16.79
0.005
+0.03%
전일 마감가:
$17.21
열려 있는:
$17.23
하루 거래량:
380.69K
Relative Volume:
0.85
시가총액:
$558.68M
수익:
$219.79M
순이익/손실:
$-57.47M
주가수익비율:
-7.807
EPS:
-2.15
순현금흐름:
$-19.25M
1주 성능:
-13.26%
1개월 성능:
-16.53%
6개월 성능:
-49.58%
1년 성능:
-31.27%
1일 변동 폭
$16.67
$17.34
1주일 범위
$15.70
$19.67
52주 변동 폭
$15.70
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
CSTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
16.79 | 558.68M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Castle Biosciences confirms UM test’s efficacy - Investing.com
Castle Biosciences (CSTL) Presents New Data on Uveal Melanoma Ri - GuruFocus
Castle Biosciences confirms UM test’s efficacy By Investing.com - Investing.com South Africa
Castle Biosciences to buy Previse - MSN
Castle Biosciences Reports Independent Validation of DecisionDx-UM Test with PRAME Gene Expression Data at ARVO 2025 - Nasdaq
Real-World Study Confirms Long-Term Performance of - GlobeNewswire
Texas public company to acquire Baltimore cancer diagnostic firm - The Business Journals
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences (CSTL) Champions Skin Cancer Awareness Initiatives | CSTL Stock News - GuruFocus
Castle Biosciences Celebrates Skin Cancer Awareness Month - GlobeNewswire
Castle Biosciences (CSTL) Rating Maintained as Price Target Lowe - GuruFocus
Castle Biosciences (CSTL) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Castle Biosciences (CSTL) Target Price Reduced Despite Strong Re - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Castle Biosciences (CSTL) Receives Price Target Adjustment by Ca - GuruFocus
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Castle Biosciences (CSTL) Receives Price Target Adjustment by Canaccord Genuity | CSTL Stock News - GuruFocus
Canaccord Adjusts Price Target for Castle Biosciences (CSTL) | C - GuruFocus
Canaccord Adjusts Price Target for Castle Biosciences (CSTL) | CSTL Stock News - GuruFocus
Castle Biosciences to Acquire Previse - FinSMEs
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - Yahoo Finance
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: - GuruFocus
Castle Biosciences Reports Strong Q1 2025 Growth - TipRanks
Castle Biosciences to Acquire GI Health Company Previse - HIT Consultant
Earnings call transcript: Castle Biosciences Q1 2025 revenue growth surpasses expectations - Investing.com Nigeria
Castle Biosciences (CSTL) to Acquire Gastrointestinal Firm Previ - GuruFocus
Castle Biosciences (CSTL) Adjusts 2025 Revenue Outlook | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Exceeds Revenue Expectations in Q1 | CSTL Stock News - GuruFocus
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Castle Biosciences to Acquire Previse for GI Test Expansion By Investing.com - Investing.com Canada
Castle Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Castle Biosciences Reports 21% Revenue Increase in Q1 2025 - TipRanks
Castle Biosciences to buy Previse (CSTL:NASDAQ) - Seeking Alpha
Castle Biosciences To Acquire Previse - marketscreener.com
Castle Biosciences to Acquire Previse | CSTL Stock News - GuruFocus
Castle Biosciences to Acquire Previse for GI Test Expansion - Investing.com
Castle Biosciences Reports First Quarter 2025 Results | CSTL Stock News - GuruFocus
Castle Biosciences Reports First Quarter 2025 Results - GlobeNewswire
Castle Biosciences to Acquire Previse - Benzinga
Castle Biosciences Acquires Johns Hopkins-Backed GI Health Company Previse to Transform Cancer Detection - Stock Titan
Wells Fargo & Company MN Boosts Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Barclays PLC Sells 3,288 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Invesco Ltd. Raises Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Monday - Defense World
New Data at DDW 2025 Further Demonstrates the TissueCypher® - GlobeNewswire
New Clinical Data Reveals How TissueCypher Test Could Transform Early Esophageal Cancer Detection - Stock Titan
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Report Preview: W - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Ou - GuruFocus
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity - The Manila Times
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity - GlobeNewswire
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.60%
1.22%
자본화:
|
볼륨(24시간):